Mesothelioma Experts Focus on Promising Immunotherapy Drug in New Article, According to Surviving Mesothelioma

Share Article

Two Canadian researchers summarize the findings on a new immunotherapy drug that may one day be used to treat mesothelioma.

Mesothelioma Treatment Advances

Promising New Therapy for Mesothelioma?

Pembrolizumab is a PD-1 inhibitor that has shown clinical activity in a variety of solid tumors.

In the wake of the FDA approval of Keytruda (pembrolizumab) for non-small cell lung cancer, researchers in Toronto have released an overview of the drug and its potential for treating other cancers, including mesothelioma. Surviving Mesothelioma has just posted an article on the new report. Click here to read it now.

In October, Keytruda was approved to treat non-small cell lung cancer by targeting cancer cells expressing a protein called PD-1.

In an article in Future Oncology, Drs. Safiya Karim and Natasha Leighl with Toronto's Princess Margaret Cancer Center explore Keytruda's potential for treating other cancers, such as malignant pleural mesothelioma, that express the same protein.

“Pembrolizumab is a PD-1 inhibitor that has shown clinical activity in a variety of solid tumors,” note the researchers.

“Because there are so few viable treatment options for patients with mesothelioma, the mesothelioma community is naturally very excited about the future possibilities for Keytruda. We'll be following news of this drug closely,” says Alex Strauss, Surviving Mesothelioma’s Managing Editor.

To read more about the Canadian report and the results of mesothelioma clinical trials with Keytruda, see Mesothelioma Community Hopeful About Newly Approved Immunotherapy Drug, now available on the Surviving Mesothelioma website.

Karim, s and Leighl, N, “Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions”, December 3, 2015, Future Oncology, Epub ahead of print,

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website